Karine Lheritier

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Safety of Remibrutinib in Chronic Spontaneous Urticaria: A Pooled Analysis of REMIX-1 and REMIX-2 Trials.

Safety of Remibrutinib in Chronic Spontaneous Urticaria: A Pooled Analysis of REMIX-1 and REMIX-2 Trials.

Journal: The journal of allergy and clinical immunology. In practice

Published: March 02, 2026

Remibrutinib Showed a Favorable Safety Profile and Sustained Efficacy in Japanese Patients with Chronic Spontaneous Urticaria Over 52 Weeks.

Remibrutinib Showed a Favorable Safety Profile and Sustained Efficacy in Japanese Patients with Chronic Spontaneous Urticaria Over 52 Weeks.

Journal: Dermatology and therapy

Published: November 04, 2025

Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies.

Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies.

Journal: The Journal of allergy and clinical immunology

Published: June 16, 2025

Remibrutinib in Chronic Spontaneous Urticaria.

Remibrutinib in Chronic Spontaneous Urticaria.

Journal: The New England journal of medicine

Published: March 05, 2025

Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.

Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.

Journal: The Journal of allergy and clinical immunology

Published: May 30, 2023

Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.

Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.

Journal: The Journal of allergy and clinical immunology

Published: May 26, 2022

Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis.

Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis.

Journal: BMC medical research methodology

Published: July 27, 2020

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.

Journal: The New England journal of medicine

Published: May 17, 2018

Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.

Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.

Journal: Clinical and experimental rheumatology

Published: July 21, 2017

Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients.

Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients.

Journal: Clinical and experimental rheumatology

Published: December 04, 2015

Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.

Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: April 29, 2015

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

Journal: The New England journal of medicine

Published: December 21, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026